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Introduction
Vesicoureteral reflux (VUR) is present in approximately 1% 
of children in North America and Europe and is associated 
with an increased risk of pyelonephritis and renal scarring 
(1,2). In children with urinary tract infection, the incidence 
is as high as 29% to 50% (1,3). When reflux coexists with 
urinary tract infection and intrarenal reflux, the child is at 
significant risk of renal scarring. 
Low-grade reflux frequently resolves, whereas high-grade 
VUR usually persists (4). The resolution rate for VUR is 
dependent on the initial grade. In general, about 80% of 
low-grade reflux resolves with medical management (5). 
Often, however, this takes considerable time. It seems that 
in children resolution of VUR grades I to III was 50% 
3.5 years after diagnosis (2,6). Grade IV VUR resolved 
much less frequently, with resolution in 50% in children 
after about 11 years (7). Sterile reflux does not cause renal 
damage, but persistent reflux of infected urine may cause 
renal damage (8,9).
Medical management is generally safe and effective in the 
absence of high voiding pressures. The International Reflux 
Study (IRS) in children, a multinational prospective study, 
compared medical and surgical management in children 
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with grades III and IV VUR. No advantage of surgical over 
medical treatment could be found with regard to renal scarring 
or renal function at the conclusion of the study (10). As for 
surgical treatment, ureteral reimplantation in open surgery 
or in laparoscopy in the hands of the pediatric urologist is 
safe and effective. 
Thus, management of children with VUR can be divided 
between medical and surgical therapy, with medical therapy 
usually offered initially, and surgery reserved for patients in 
whom medical management is unsuccessful. Most patients 
“fail” medical management because of persistent reflux 
into adolescence, or to continue to develop urinary tract 
infections, or they failure to comply with maintenance 
prophylactic regimens.
Technical and surgical considerations
According to VUR guidelines, after a diagnosis of VUR, all 
children are placed on antibiotic prophylaxis (1,11,12).
In general, patients with VUR are nearly always followed 
for at least 1 year, regardless of reflux grade. In many of 
these children, the grade of reflux will be lowered as the 
infection is controlled and the children begin to void more 
comfortably (5,13).
As a result of reduced severity of reflux and increased 
bladder volume, anti-reflux surgery is safer and more 
effective in older infants. After the first year, the child 
undergoes follow-up nuclear cystography, which measures 
the bladder volume when the bladder is filled to capacity, 
the bladder volume at which reflux is first noted, and the 
volume of urine refluxing into either ureter (7,14).
We carefully ask about the child’s voiding pattern, 
urgency, or infrequent voiding, all of which can be 
suggestive of dysfunctional voiding, must be identified prior 
to surgery. If symptoms of dysfunctional voiding can be 
elicited, care should be taken to improve the coordination 
of voiding before proceeding to surgical treatment of reflux, 
since the failure rate following anti-reflux surgery in these 
children is greater. If high-volume reflux persists at the 
second study and the patient is not a dysfunctional voider, 
surgical correction should be considered.
We underline that medical management in the absence 
of infection is safe but may not be the most effective way to 
manage the patient with high-volume VUR. Considering 
the prospect of numerous radiologic studies and years of 
antibiotic prophylaxis without good odds of spontaneous 
resolution of VUR, many families elect to proceed with 
surgery, particularly if a relatively less morbid (i.e., 
laparoscopic or endoscopic) approach is available. There are 
now 3 different techniques available to correct surgically 
the VUR (6,15). The open approach, that consist in to open 
the bladder and to reimplant the ureter according to Cohen 
or Politano technique, this technique now is indicated 
rarely only in high grade reflux when a ureteral tailoring is 
necessary. Laparoscopy ureteral reimplantation according 
to Lich-Gregoire technique is indicated in reflux grade II 
to IV, and this technique has the advantage to do not open 
the bladder and to reimplant the ureteres extravesically with 
a wonderful post-operative period (4,6,16). Endoscopic 
treatment of VUR has obvious advantages over conventional 
approaches. Endoscopic correction is usually done on an 
outpatient basis-The hospital stay is short, and there is no 
surgical scar.
As a result, overall hospital charges are decreased. 
Because of the lower morbidity of endoscopic surgery and 
lower costs compared to open procedures, one could argue 
that additional patients should be offered surgery rather 
than prophylaxis as the initial treatment. Alternatively, 
Stenberg and colleagues recently recommended that most 
children with VUR managed conservatively with antibiotics 
for longer than 1 year be offered endoscopic treatment, 
specifically with dextranomer/hyaluronic acid copolymer, as 
an alternative to long-term antibiotic prophylaxis or open 
surgery (6,13,17,18).
Unfortunately, because endoscopic repair is less 
successful in patients with high-grade primary VUR, 
multiple procedures are frequently necessary. This translates 
into additional costs and hospital stays for repeat surgery. 
In addition, even after successful endoscopic correction, 
reflux can recur. As a result, there is a risk that the child 
who is removed from antibiotic prophylaxis and suffers a 
recurrence may return with pyelonephritis and a new scar, 
the very thing we try to prevent with anti-reflux surgery. For 
these reasons, we tend to offer endoscopic correction only 
to the few with low-grade primary VUR in whom medical 
management has failed or to the few who have persistent 
VUR after ureteroneocystostomy. On the other hand, 
endoscopic correction is an attractive alternative for some 
more complicated cases in which ureteroneocystostomy is 
probably unnecessary (18,19).
Pre-operative work-up 
Nearly all patients undergo ultrasonography as the initial 
study to assess the shape of the kidney and the presence 
of scarring. If significant scarring exists, the volume of 
284 Okawada et al. Vesico-ureteral reflux in children: endoscopic approaches
© Translational Pediatrics. All rights reserved. Transl Pediatr 2016;5(4):282-290tp.amegroups.com
renal parenchyma is small, the kidney looks echo dense, or 
the cortico-medullary junctions are obscure, a renal scan 
is obtained to further assess preoperative function and 
drainage (7,19,20). 
If function is poor (<10%), consideration should be given 
to removal of the kidney and ureter rather than correction 
of the VUR (8,21). Before any kind of surgery for VUR 
a cystography is mandatory, we have 2 possibilities: the 
classical cystography that gives a perfect morphological 
picture of the bladder, of the ureters and permits a clear 
classification of the VUR but with the disadvantage of 
an high quantity of radiations. The second option is the 
cystoscintigraphy that is less morphological accurate but it 
gives less radiations that the classical cystography.
Rarely, a secondary ureteropelvic junction (UPJ)
obstruction exists (9,21). If a UPJ obstruction is suspected 
to coexist with reflux, correction should be made prior 
to, or at the time of, anti-reflux surgery if the obstruction 
appears to be primary (5,22). Otherwise, UPJ obstruction 
suspected to be secondary to high-grade VUR should be 
carefully monitored following anti-reflux surgery (2,23). 
Patients with posterior urethral valves, neuropathic bladder, 
or severe dysfunctional voiding should be considered for 
anti-reflux surgery only after very careful deliberation. 
Vesicostomy is usually a better option. In many cases, 
high-volume VUR effectively improves capacity in the 
valve bladder and should be allowed to remain as long as 
the patient has no upper urinary tract infection. Whether 
attempting endoscopic or open or laparoscopic repair of 
VUR, the bladder volume must be adequate to allow for 
low-pressure storage following voiding. 
If bladder capacity is suspect, attempts to correct reflux 
by any means usually fail. Because successful subureteral 
injection requires at least some type of submucosal ureteral 
tunnel in which to place the implant, lower grades of reflux 
are more easily corrected than higher grades of reflux 
(12,24). If subureteral correction is planned in a patient with 
high-grade VUR, the patient and his or her family must 
be cautioned that additional attempts may be necessary 
to correct the problem. Specifically, the risks of persistent 
treflux and the possible need for additional surgery should 
be outlined and compared with the risks of open surgical 
repair (3,7,25). The risk of obstruction of the ureter, both 
transient and long term, should also be outlined, along with 
the steps needed to correct such an eventuality. Urinary 
tract infection, bleeding, obstruction, and persistent reflux 
can occur following endoscopic or open surgery (3,24,26). 
Risks specific to the implant material are particularly 
important considerations prior to planning endoscopic 
surgery. The relative risks and benefits of each substance 
are considered under the description of each substance 
(6,27,28).
Patient preparation
In children, general anesthesia is administered via 
endotracheal intubation or laryngeal mask airway with no 
additional special requirements. The patient is placed in 
the dorsal lithotomy position. The legs should be separated 
enough to provide easy access even to a very lateral ureteral 
orifice. Special imaging equipment is not necessary. 
Endoscopic camera equipment is helpful because it allows 
the assistant and the surgeon to coordinate their efforts 
during the injection.
Instrumentation 
Cystoscopes and needles 
Cystoscopic equipment varies with the implant. In general, 
the most widely used substances, require little in the way 
of extensive equipment. Substance can be injected through 
a needle as small as 3.7 or 5 French without too much 
difficulty with a hand-held conventional syringe. No special 
equipment other than conventional endoscopic equipment 
is needed. The majority of pediatric urologists prefer to 
use a 9.5–10 French pediatric operative cystoscope with a 
working channel of 5Ch to allow the needle to be inserted 
without problem. 
In general, the larger the needle the easier the injection. 
Using a hand-held gun to increase the force of injection can 
help for some substances that are denser than the others. 
Many practitioners are using conventional endoscopes with 
a flexible needle some others prefer to use a rigid needle, 
but this choice remains a surgeon preference.
Implant substances
Over the years, endoscopic enthusiasts have researched 
many substances, But only few materials are widely used. 
The following are a few of the more commonly. Used 
materials and substances of historical and experimental 
interests.
Deflux 
One of the greatest advances made for the endoscopic 
285Translational Pediatrics, Vol 5, No 4 October 2016
© Translational Pediatrics. All rights reserved. Transl Pediatr 2016;5(4):282-290tp.amegroups.com
correction of VUR was developed by Stenberg and 
Läckgren and is now the most widely used implant. Deflux 
is a suspension of dextranomer microspheres (80 to 120 μm) 
in sodium hyaluronate solution (NaHa) (1,5-7). 
The dextranomer particles are cross-linked dextran 
polymers, and the NaHa is an endogenous polysaccharide 
(5,7,10).
In most cases, implant volume of 0.5 to 1.5 mL is 
effective in correcting VUR (7,18,28). Deflux was approved 
for use in the United States in 2002. Since that time, its 
use in North America has exploded, and now, nearly all 
pediatric urologists have some experience with it (6,19,23).
Polytef 
O’Donnell and associates developed the technique and 
popularized it in1991, O’Donnell estimated that more 
than 3,000 ureters had been treated in Europe and the 
United States (5,7,10,18). Its injection characteristics allow 
relatively easy implantation even in laterally placed ureters. 
Polytef is a 50% suspension of Teflon particles in glycerol. 
The Teflon particle size ranges from 4 to 100 μm, with more 
than 90% smaller than 40 μm (19,23,28). Perhaps more 
disturbing, migrated particles in animal model as large as 
80 μm were found in the pelvic lymph nodes, kidneys, spleen, 
and lung and in the subarachnoid space of the brain stem and 
cerebral hemispheres. The tissue reaction associated with the 
migrated particles was variable (7,10,18).
Information regarding migration in humans is less clear. 
No substance had been as easy to use up until 2002 when 
the US Food and Drug Administration (FDA) approved 
Deflux for use in the United States. At that time, even those 
with large experiences using Polytef paste migrated over to 
the use of Deflux (7,10,18).
Collagen (Zyplast) 
Because of the uncertainty surrounding the long-term 
effects of particle migration and local tissue reaction to 
Polytef paste and recognizing the efficacy of the subureteral 
Teflon injection (STING), Peters and Jeffs began 
experimenting with a glutaraldehyde cross-linked bovine 
collagen preparation (Zyplast) as an alternative (5,6,7,10,28).
Cross-linked bovine collagen had been widely used for 
years in cardiac valves as a hemostatic agent and, in the 
injectable form, as a soft tissue substitute (7,10). Zyplast is 
bovine corium collagen, which is solubilized by exposure to 
pepsin in acetic acid and purified by ultrafiltration and ionex 
change chromatography (6,18).
Following purification, he collagen is reconstituted in 
a pH-neutral solution, harvested, and re-suspended in 
saline solution to provide non-cross-linked collagen. To 
this substance is added purified glutaraldehyde in a final 
concentration of 0.0075% to cross link the reconstituted 
collagen fibrils (18,23,28). The added glutaraldehyde binds 
adjacent collagen fibrils to improve the integrity of the 
implant after injection (23).
Zyplast elicits little local tissue reaction and no 
granuloma formation when injected beneath the 
urothelium. Zyplast is more fluid than Polytef (7,10,18). 
Despite a relatively rapid increase in popularity in collagen 
in the late 1980s and early 1990s, by the end of the 1990s, 
most centers that were initial enthusiasts of collagen 
injections began to perceive that the implant was breaking 
down relatively quickly after 24 months following initial 
and repeat injections (5,6,23,28).
Particulate silicone microimplants (Macroplastique) 
In an effort to reduce migration of implant particles 
while maintaining a durable implant, Schulman began 
to experiment with particulate silicone macroparticles 
(Macroplastique) (6).
Macroplastique is 40% vulcanized polydimethylsiloxane 
particles in a 60% water-soluble carrier medium composed 
of low-molecular-weight polyvinylpyrrolidone (6,7,10). 
The advantage of this substance over Polytef is that it 
contains few small particles. Since the largest macrophages 
are approximately 80 μm, particles smaller than 80 μm 
can migrate via the macrophage to distant organs (6,28). 
Macroplastique implant particles range in size from 16 to 
409 μm (average 171 μm) (10,28). This results in fewer 
particles small enough to migrate.
Despite the larger average particle size, limited migration 
of a few smaller particles to the lung in rabbits and to the 
spleen in dogs has been reported (18,23,28).
Despite the small number of migrated particles, even 
minimal migration is cause for concern and prevented 
Macroplastique from gaining popularity in the United 
States, although it has been used in Europe and Canada 
with success that approaches that of Deflux (6,23).
Technique of injection
The first report of a technique of injection was reported 
by O’Donnell and Puri (5). The principle of the STING is 
identical to that of open ureteroneocystostomy—to create a 
solid support behind the refluxing intravesical ureter (5,7). 
With the STING, this support is created by injection of the 
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implant beneath the affected ureteral orifice (19).
The patient is placed in the dorsal lithotomy position 
and cystoscopy is performed. The patient’s legs should 
be wide enough apart to provide good visualization and 
access to each ureter. The location and configuration of the 
ureteral orifice are carefully evaluated. Lateral or gaping 
ureteral orifices are more difficult to treat, particularly with 
less viscous substances.
After cystoscopic examination, the bladder is drained to 
provide just enough distention to allow inspection of the 
trigone. With the bladder less full, the ureteral tunnels are 
easier to inject (5,7).
The appropriate needle is primed to prevent injection 
of air or irrigant at the implant site and advanced into the 
orifice at the 6-o’clock position (19). The needle is then 
advanced the appropriate distance to support the trigone 
but not so far as to result in injection outside Waldeyer’s 
sheath into the detrusor or extravesical space (5,7). The 
needle must be just under the urothelium (19). The initial 
injection should be made very gently to assess the location 
of the implant.
If an immediate hump is not identified, the needle is 
either buried too deep in the trigone or advanced too far 
into Waldeyer’s sheath and should be repositioned (5). The 
injection is then continued to raise an implant appropriate 
to close the ureteral orifice and provide significant backing 
to the ureter (19). As the injection proceeds, the distal 
ureter flattens and the orifice closes, assuming a slit-like 
configuration near the top of the implant mound at the 
conclusion of the procedure. Depending on the substance, 
the implant should slightly overcorrect (or over-close) 
the ureteral orifice. The delivery agent (glycerin, saline 
solution, or sodium hyaluronate) is absorbed within the first 
month, leaving the implant behind (5,7).
This may reduce the precision of the injection somewhat, 
but this phenomenon is readily overcome as one becomes 
familiar with the technique (19). Most refluxing ureters 
require 1.0 mL of implant, and many need as little as 0.05 to 
0.2 mL (5,7). The needle should be kept in position for 30 
to 60 s after injection to prevent extrusion of the implant. A 
ureteral catheter can be helpful in laterally placed ureters or 
in those with gaping orifices (5,7). The catheter is used to 
elevate the ureteral orifice to allow more precise placement 
of the needle just beneath the urothelium.
Duplex systems can be injected without difficulty (19). 
The injection is placed just superficial to the wall of 
the upper-pole ureter. Care must be taken to prevent 
perforation of the upper-pole ureter, which will not always 
be apparent. Placement of a ureteral catheter is particularly 
helpful in duplex systems. The injection is identical to that 
for single-system ureters and a similar appearance at the 
end of the injection is desirable.
Repeat injections may be necessary. If reflux recurs or 
if, despite several attempts to correct it, reflux still exists, a 
second or even a third or fourth injection may be necessary. 
At the time of repeat injection, the previous implant is often 
seen lateral or proximal to the ureteral orifice. The same 
injection technique can then be used to correct the reflux. 
In some cases, the second injection may be more satisfactory 
than the first since scar-ring beneath the ureteral orifice may 
tend to stabilize the implant site and make extravasation 
outside Waldeyer’s sheath less likely (5,7). 
Patients with persistent VUR following ureteroneocystostomy 
may also be treated. Following unsuccessful ureteral 
advancement procedures, the implant should be placed 
as previously described, just beneath the ureteral orifice. 
Following an unsuccessful cross-trigonal reimplantation, 
the injection should be at right angles to the path of the 
ureter at or near the ureteral orifice (19).
The technique employed by Kirsch and colleagues for 
implantation of dextranomer/hyaluronic acid copolymer 
is so similar to the STING procedure described above 
that they named their technique the “modified STING” 
(10,18,22). A 9.5 or 10 French pediatric cystoscope with 
an offset lens allowing for direct passage of the 3.7 French 
needle is preferred (10). The needle is thus inserted unbent 
and can then be properly manipulated without inadvertent 
damage to the mucosa of the bladder and bladder neck, 
causing bothersome bleeding. The bladder is filled to half 
or three-quarters volume, permitting visualization of the 
ureteral orifice and intraluminal ureter (22).
This volume will prevent distortion and tension 
of the ureteral submucosa caused by overdistention. 
Hydrodistention of the ureter is performed by directing 
a pressurized jet of irrigant at the ureteral orifice to 
open it before injection (22). This maneuver allows for 
identification of the ureteral submucosal injection site (18).
With hydrodistention, the needle is inserted (with the 
bevel up) approximately 4 mm into the submucosa of the 
mid to distal ureteral tunnel at the 6-o’clock position (18). 
The needle used has been modified to have a black mark 
4 mm proximal from the bevel. A small amount of implant 
(less than 0.1 mL) is injected to confirm location. To avoid 
leakage of material and ensure good visualization, continued 
irrigation is avoided. The cystoscope is then brought back 
to the bladder neck with care not to dislodge the needle (22).
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This cystoscope position allows for observation of 
ineffective caudal, medial, or lateral tracking of the implant 
that might not otherwise be noticed if only the ureteral 
orifice and tunnel are in the visual field (18).
The needle tip can be repositioned for another injection 
if optimal implantation is not achieved, but multiple needle 
holes can lead to leakage of material (10).
A fully coapted ureter is the end result of a proper 
implantation. Kirsch and colleagues emphasize that the 
most critical part of the procedure is to place the needle in 
the submucosal plane so that material can travel cephalad 
within the ureteral submucosa, maximizing the length of 
ureteral coaptation. Volume of injected material ranges 
from 0.5 to 1.5 mL per ureter (10,18).
Hydrodistention of the ureter after injection should 
reveal a properly coapted ureter. Observation for efflux 
from the ureteral orifice to confirm antegrade flow of 
urine is not necessary because Kirsch and his colleagues 
have not had any incidents of hydronephrosis from this 
modified STING technique (22). The modified STING 
had significantly improved the reflux-free rate to 92% from 
79% for the standard STING (10,18).
A learning curve was observed by Kirsch and colleagues 
with their previous injection technique (22).
Postoperative care
Patients are continued on antibiotic prophylaxis for about 
3 months, at which time a voiding cystogram is obtained. 
If reflux is no longer present, antibiotic prophylaxis is 
discontinued, and the patient is followed closely for signs of 
infection. 
It is essential that the patient and his or her family be 
aware that reflux may return if migration or breakdown of 
the implant occurs. 
The child’s family is instructed to return if the child 
shows signs of febrile urinary tract infection. No subsequent 
voiding cystograms are obtained unless signs of upper 
urinary tract infection are present. Ultrasound imaging of 
the kidneys and bladder is performed annually to assess the 
position, size, and location of the implant.
Results
Despite the array of substances emerging for correction 
of VUR, only four—Deflux, Polytef, collagen, and 
Macroplastique—have been used in humans in large enough 
numbers to enable assessment of effectiveness (5,7).
As for Deflux, in the first-ever human trial with Deflux, 
Stenberg and Läckgren 40 noted excellent success in both 
low and high grades of reflux (1,6,7,18,28).
Their initial report involved patients with primarily 
grade III and IV reflux with an overall success in 62.7% of 
ureters with a single injection was reported in this initial 
series (7,19).
Kirsch and colleagues recently reported a 76% reflux-
free rate for 137 cases treated with a single injection with 
at least 3 months of follow-up (10,18). Puri and colleagues 
had even better results, with 86% cure rate after a single 
injection with median follow-up of 6 months. These 
findings suggest that Deflux is safe for use in children 
with VUR (5,19). Because of its organic composite, large 
particle size, and minimal local tissue reaction, Deflux may 
be a more attractive choice for injection than Polytef or 
Macroplastique (6,18,28).
As for Polytef was the most widely used substance (1). 
Puri and colleagues reported treatment in 12,251 ureters 
in 8,332 children from 53 pediatric urologists and pediatric 
surgeons at 41 centers worldwide (5,7). This study included 
patients with all grades of VUR, but 61% of the ureters 
were grade III or IV (5,7). Collectively, 89% of ureters were 
rendered reflux-free with up to four injections (19).
Nearly all (93%) patients underwent STING as an 
outpatient procedure (19).
Most centers have obtained cystograms at 3 months, 
1 year, and 3 years after implantation. Seventy percent of 
all patients treated have remained cured after 1 year. Puri 
and colleagues report a 93% persistent cure rate in infants 
followed from 1 to 9 years (5,6,7,19).
As for Collagen results following collagen injection 
have not been as favorable as those with Deflux or Polytef. 
Leonard and colleagues reported 75% of ureters corrected 
at 1 month. Of that group, 79% had a persistent cure at 
1 year, for an overall success rate of 61% in primary non 
duplicated ureters. Success was not as good for higher 
grades of reflux (5). A few patients were cured at 1 month 
and had recurrent reflux at 1 year (7,19).
Frey and colleagues reported recurrence rates of 
up to 50% following collagen injection with many late 
recurrences, but not one episode of pyelonephritis was 
noted in their large series (7).
Morbidity from endoscopic injection of collagen is 
minimal. The theoretical risk of an autoimmune response 
with collagen injection is probably unfounded. As for 
Macroplastique an interesting sudy reported that it has been 
injected in 114 children with grade II to IV reflux (6,7,19). 
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An initial report quoted a cure rate higher than 90% with 
follow-up between 6 and 30 months.
More recently, other colleagues reported a similar cure 
rate of 92% using a single injection with an average follow-
up of 12 months. Like Polytef, however, concerns of particle 
migration will likely prevent widespread popularity in the 
United States (1,19,23,28).
Discussion
Various options are available for the treatment of children 
with vesicoureteral reflux (VUR). For many years, ureteral 
reimplantation has been considered the gold standard in 
the treatment of high-grade VUR (6). However, it is an 
invasive procedure and results in longer hospital stay, and 
also is not free of complications such as vesicoureteral 
obstruction (1,6).
In the past 30 years, the therapeutic approach to 
children with VUR has undergone a dramatic evolution 
from mainly surgery, as soon as VUR was detected, 
toward a conservative approach with continuous antibiotic 
prophylaxis to a minimally invasive approach using 
endoscopic or laparoscopic approach, or to an active 
surveillance without prophylaxis in asymptomatic patients 
without infections (6,10).
Analyzing the international literature, it is evident that 
the treatment selection and decision for treating VUR in a 
child is an individualized process. As for currently available 
surgical approaches, there are the classic open approach 
using Cohen or Politano-Leadbetter ureteral reimplantation, 
the endoscopic approach using bulking agents, and the 
laparoscopic approach using extravesical reimplantation 
according to Lich Gregoir, or laparoscopic intravesical 
reimplantation described by Yeung and Valla (6,16,25).
A recent meta-analysis of randomized controlled trials 
concluded that little benefit from additional surgery over 
antibiotics alone is measurable (6,9,14,19,23).
Although successful correction of reflux was associated 
with fewer febrile urinary tract infections, it was difficult 
to measure a surgical benefit in terms of fewer renal scars, 
even with long-term follow-up. With this in mind, surgeons 
must continue to compare the value of endoscopic VUR 
correction to that of the standard laparoscopic or open 
reimplant (17,21).
Until we have a technique and a substance that equals 
or surpasses the 95% success rate following open surgical 
repair, endoscopic correction will continue to be considered 
an alternative to ureteroneocystostomy, despite the 
increased pain, hospital stay, and scarring following an open 
repair (6,18).
Even with widespread experience, the success rate in 
high-grade reflux with a single injection of any of the 
available substances still fails to equal that following open 
or laparoscopic ureteroneocystostomy.
The initial results following a single injection for each of 
the current substances are still too low for many parents. 
A meta-analysis conducted by Elder and colleagues 
showed success rates of 57% to 77% for a single injection 
of the four most widely used substances (4,18). The overall 
resolution rate was 72% (4,18). Combining these data, 
about 50% of children with a high grade of reflux will not 
be cured without multiple injections (4,6,18). Additional 
treatments, however, improve the success rates. Elder’s 
meta-analysis reports a success rate of 85% with multiple 
treatments (4,18).
With these results, despite the need for additional 
anesthetics, many families elect an endoscopic treatment 
approach to avoid the trauma of open surgery. Even if the 
cure rate does not equal that of open surgical correction, 
additional protection may be provided from ascending 
infection while awaiting spontaneous resolution of reflux. 
When one considers the multiple factors resulting 
in renal scarring, suggesting minimal benefit of open 
surgery over prophylactic antibiotics, it becomes more 
and more difficult to recommend ureteroneocystostomy 
as an alternative for those families wishing to discontinue 
antibiotic prophylaxis (15,24). The substantial increase in 
pain and duration of hospitalization may not be worth the 
convenience afforded by the open approach of being off 
prophylactic antibiotics. In a study from Italy, 80% of the 
parents with children diagnosed with grade III VUR chose 
endoscopic treatment over prophylactic antibiotics (5%) 
or open reimplant (2%) (6,7,9,22). The parents were given 
detailed information (including expected risks, benefits, 
cure rates, and mechanisms of action) on all three treatment 
options prior to completing a treatment preference 
questionnaire (6,7,9,22).
More than 3 decades have passed since the initial report 
by O’Donnell and Puri of the use of STING in their first 
13 patients (5,7). The technique is sound. The debate over 
optimal implant material appears to be over, as previously 
differing camps and proponents of other substances have 
adopted the use of dextranomer/hyaluronic acid copolymer 
throughout the world. Use of other materials has become 
less common as the use of Deflux gains momentum, but 
more experience and long-term follow-up are needed. 
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With continued acceptance, success, and minimal to no side 
effects from the use of bulking agents, endoscopy will gain a 
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